CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Tisotumab vedotin (HuMax-TF-ADC)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02552121
NCT02552121Phase 2Completed
CompareCT.gov

Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

Seagen Inc.·interventional·Posted Sep 16, 2015·Updated Apr 8, 2021

In Brief

A Phase 2 clinical trial evaluating Tisotumab vedotin (HuMax-TF-ADC) for Ovary Cancer and 6 related conditions. Completed, enrolled 33 participants across 16 sites in 5 countries.

Detailed Summary

The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer (NSCLC)
CountriesBelgium, Denmark, Hungary, United Kingdom, United States
CollaboratorsGenmab

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 16, 2015
Enrollment StartNov 30, 2015
Primary CompletionDec 13, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.8 years ago

Interventions

Tisotumab vedotin (HuMax-TF-ADC)drug